Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics by study (budesonide/formoterol 160/4.5 μg and formoterol 4.5 μg arms only)

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

CharacteristicSUN (n = 989)SHINE (n = 561)US3 (n = 807)RISE (n = 1219)
Age, years63.0 (40–88)63.3 (41–89)63.1 (40–87)63.5 (40–87)
Male, n (%)631 (63.8)374 (66.7)490 (60.7)698 (57.3)
Female, n (%)358 (36.2)187 (33.3)317 (39.3)521 (42.7)
Race, n (%)
 White914 (92.4)523 (93.2)667 (82.8)1119 (91.8)
 Black23 (2.3)20 (3.6)33 (4.1)39 (3.2)
 Asian5 (0.5)2 (0.4)10 (1.2)17 (1.4)
 Other47 (4.8)16 (2.9)96 (11.9)44 (3.6)
Former smoker, n (%)573 (57.9)319 (56.9)516 (63.9)655 (53.7)
Current smoker, n (%)416 (42.1)242 (43.1)291 (36.1)564 (46.3)
No. exacerbations in previous year1.8 (1–13)1.6 (0–8)1.7 (1–12)1.4 (1–7)
Post-FEV1, L1.18 (0.35–3.26)1.20 (0.30–3.29)1.11 (0.34–2.96)1.38 (0.34–3.6)
Post-FEV1, % predicted38.9 (13–92)39.3 (10–103)37.7 (12–77)48.7 (16–78)
FEV1/FVC ratio0.49 (0.20–0.85)0.48 (0.20–0.82)0.47 (0.16–1.00)0.49 (0.19–0.75)
Eosinophils, ×109/L, geometric mean (range)0.18 (0.01–1.47)0.18 (0.01–1.01)0.13 (0.01–2.51)N/Aa
SGRQ total score54.9 (7–100)54.9 (14–100)57.5 (6–99)46.7 (0–97)
  1. Data presented as mean (range) unless otherwise stated
  2. aLaboratory data was not assessed in RISE; therefore, no baseline data are available for eosinophils
  3. FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, N/A Not applicable, SGRQ St George’s Respiratory Questionnaire
  4. For full baseline characteristics, see Additional file 1: Table S2